Comparative outcomes of leukotriene receptor antagonists and long-acting b-agonists as add-on therapy in asthmatic patients: A population-based study

Journal of Allergy and Clinical Immunology

Volumn 132, Issue 1, 2013, Pages 63-69

  Sadatsafavi, Mohsen ^a,b,c   Lynd, Larry ^c   Marra, Carlo ^c   Bedouch, Pierrick ^d   FitzGerald, Mark ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER COASTAL HEALTH   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Administrative data; Asthma; Canada; Costs; Inhaled corticosteroids; Leukotriene receptor antagonists; Long acting agonists; Outcome research

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING BETA AGONIST; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADOLESCENT; ADULT; ARTICLE; ASTHMA; CHILD; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DATA BASE; DRUG COST; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTPATIENT; PRIORITY JOURNAL; PROPENSITY SCORE; SCHOOL CHILD; TREATMENT OUTCOME;

EID: 84882841490     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2013.02.007     Document Type: Article

References (42)

1. Global Initiative for Asthma (GINA). GINA report, global strategy for asthma management and prevention. Available at: http://www.ginasthma.org/pdf/ GINA-Report-2010.pdf. Accessed February 5, 2013.
2. Accordini S, Bugiani M, Arossa W, Gerzeli S, Marinoni A, Olivieri M, et al. Poor control increases the economic cost of asthma. A multicentre population-based study. Int Arch Allergy Immunol 2006;141:189-98.
3. Vollmer WM, Markson LE, O'Connor E, Sanocki LL, Fitterman L, Berger M, et al. Association of asthma control with health care utilization and quality of life. Am J Respir Crit Care Med 1999;160:1647-52.
4. The National Asthma Education Prevention Program (NAEPP II) guidelines for the treatment of asthma: implications for the pharmacist (manuscript updated December 2000). 2009. Available at: http://www.inetce.com/articles/pdf/146-000- 01-001-H01.pdf. Accessed February 5, 2013.
5. Canadian Thoracic Society. 2010 CTS guideline-asthma management continuum-consensus summary for children six years of age and over, and adults. Available at: http://www.respiratoryguidelines.ca/canadian-thoracic-society- asthma-management-continuum-%E2%80%93-2010-consensus-summary-for-children-six- year. Accessed February 5, 2013.
6. Expert panel report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. JAllergy Clin Immunol 2007;120(suppl):S94-138.
7. Nelson HS, Busse WW, Kerwin E, Church N, Emmett A, Rickard K, et al. Fluti-casone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000;106:1088-95.
8. Fish JE, Israel E, Murray JJ, Emmett A, Boone R, Yancey SW, et al. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest 2001;120:423-30.
9. Ringdal N, Eliraz A, Pruzinec R, Weber HH, Mulder PGH, Akveld M, et al. The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. Respir Med 2003;97:234-41.
10. Ducharme FM, Lasserson TJ, Cates CJ. Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database Syst Rev 2011;(5):CD003137.
11. Latry P, Pinet M, Labat A, Magand J-P, Peter C, Robinson P, et al. Adherence to anti-inflammatory treatment for asthma in clinical practice in France. Clin Ther 2008;30(Spec No):1058-68.
12. Ducharme FM, Noya FJD, Allen-Ramey FC, Maiese EM, Gingras J, Blais L. Clinical effectiveness of inhaled corticosteroids versus montelukast in children with asthma: prescription patterns and patient adherence as key factors. Curr Med Res Opin 2012;28:111-9.
13. Price D, Musgrave SD, Shepstone L, Hillyer EV, Sims EJ, Gilbert RFT, et al. Leu-kotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med 2011;364:1695-707.
14. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996;312:1215-8.
15. Persaud N, Mamdani MM. External validity: the neglected dimension in evidence ranking. J Eval Clin Pract 2006;12:450-3.
16. Sanson-Fisher RW, Bonevski B, Green LW, D'Este C. Limitations of the randomized controlled trial in evaluating population-based health interventions. Am J Prev Med 2007;33:155-61.
17. Allen-Ramey FC, Bukstein D, Luskin A, Sajjan SG, Markson LE. Administrative claims analysis of asthma-related health care utilization for patients who received inhaled corticosteroids with either montelukast or salmeterol as combination therapy. J Manag Care Pharm 2006;12:310-21.
18. Stempel D, O'Donnell J, Meyer J. Inhaled corticosteroids plus salmeterol or mon-telukast: effects on resource utilization and costs. J Allergy Clin Immunol 2002; 109:433-9.
19. British Columbia Ministry of Health. Population Data BC. Available at: http://www.popdata.bc.ca/data. Accessed November 20, 2011.
20. Pink GH, Bolley HB. Physicians in health care management: 4. case mix groups and resource intensity weights: physicians and hospital funding. CMAJ 1994; 150:1255-61.
21. Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax 2002;57:880-4.
22. Gu XS, Rosenbaum PR. Comparison of multivariate matching methods: structures, distances, and algorithms. J Comput Graph Stat 1993;2:405-20.
23. Glynn RJ, Schneeweiss S, Stürmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006;98: 253-9.
24. Weitzen S, Lapane KL, Toledano AY, Hume AL, Mor V. Principles for modeling propensity scores in medical research: a systematic literature review. Pharmacoe-pidemiol Drug Saf 2004;13:841-53.
25. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comor-bidity index. J Clin Epidemiol 1994;47:1245-51.
26. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999;319:670-4.
27. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006;40:1280-8.
28. Yong PL, Werner RM. Process quality measures and asthma exacerbations in the Medicaid population. J Allergy Clin Immunol 2009;124:961-6.
29. Sadatsafavi M, Lynd L, Marra C, Carleton B, Tan W, Sullivan S, et al. Direct health care costs associated with asthma in British Columbia. Can Respir J 2010;17:74-80.
30. Bedouch P, Marra CA, Fitzgerald JM, Lynd LD, Sadatsafavi M. Trends in asthma-related direct medical costs from 2002 to 2007 in British Columbia, Canada: a population based-cohort study. PLoS One 2012;7:e50949.
31. Latest release from the Consumer Price Index. Available at: http://www.statcan.ca/english/Subjects/Cpi/cpi-en.htm. Accessed February 5, 2013.
32. Austin PC. Balance diagnostics for comparing the distribution of baseline covari-ates between treatment groups in propensity-score matched samples. Stat Med 2009;28:3083-107.
33. Gardner W, Mulvey EP, Shaw EC. Regression analyses of counts and rates: Pois-son, overdispersed Poisson, and negative binomial models. Psychol Bull 1995;118: 392-404.
34. Mihaylova B, Briggs A, O'Hagan A, Thompson S. Review of statistical methods for analysing healthcare resources and costs. Health Econ 2011;20:897-916.
35. Stempel D, Meyer J, Stanford R, Yancey S. One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma. J Allergy Clin Immunol 2001;107:94-8.
36. Allen-Ramey FC, Duong PT, Goodman DC, Sajjan SG, Nelsen LM, Santanello NC, et al. Treatment effectiveness of inhaled corticosteroids and leukotriene modifiers for patients with asthma: an analysis from managed care data. Allergy Asthma Proc 2003;24:43-51.
37. Dorais M, Blais L, Chabot I, LeLorier J. Treatment persistence with leukotriene receptor antagonists and inhaled corticosteroids. J Asthma 2005;42:385-93.
38. Tan H, Sarawate C, Singer J, Elward K, Cohen RI, Smart BA, et al. Impact of asthma controller medications on clinical, economic, and patient-reported outcomes. Mayo Clin Proc 2009;84:675-84.
39. Zeiger RS, Hay JW, Contreras R, Chen W, Quinn VP, Seal B, et al. Asthma costs and utilization in a managed care organization. J Allergy Clin Immunol 2008;121: 885-92.e5.
40. Lee TA, Chang C-L, Stephenson JJ, Sajjan SG, Maiese EM, Everett S, et al. Impact of asthma controller medications on medical and economic resource utilization in adult asthma patients. Curr Med Res Opin 2010;26:2851-60.
41. Aaron SD, Vandemheen KL, Boulet L-P, McIvor RA, Fitzgerald JM, Hernandez P, et al. Overdiagnosisofasthmainobese and nonobese adults. CMAJ 2008;179:1121-31.
42. Travers J, Marsh S, Williams M, Weatherall M, Caldwell B, Shirtcliffe P, et al. External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax 2007;62:219-23.